Prescribing information

 

This site contains information for healthcare professionals about ILARIS.

ILARIS is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older1:

  • Cryopyrin-associated periodic syndromes (CAPS), including:
    • Muckle-Wells syndrome (MWS)
    • Neonatal-onset multisystem inflammatory disease (NOMID)/chronic infantile neurological, cutaneous, articular syndrome (CINCA)
    • Severe forms of familial cold autoinflammatory syndrome (FCAS)/familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash.
  • Tumour necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS).
  • Hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD).
  • Familial Mediterranean fever (FMF). ILARIS should be given in combination with colchicine, if appropriate.

ILARIS is the first and only selective IL-1β inhibitor for the treatment of FMF, HIDS/MKD, TRAPS and CAPS in adults, adolescents and children aged ≥2 years1

ILARIS is a fully human monoclonal antibody that neutralises IL-1β to reduce inflammation.1

IL-1β is a proinflammatory cytokine that plays a key role in autoinflammatory diseases.1,2

 Image showing the mode of action of ILARIS in periodic fever syndromes

Image created using information from references 1–3.

CAPS, cryopyrin-associated periodic syndromes; FMF, familial Mediterranean fever; HIDS, hyperimmunoglobulin D syndrome; IL, interleukin; MKD, mevalonate kinase deficiency; TRAPS, tumour necrosis factor receptor-associated periodic syndrome.

References     

  1. ILARIS® (canakinumab) Summary of Product Characteristics.     
  2. Lachmann HJ et al. Arthritis Rheum 2011;63(2):314–324.     
  3. Lin YT et al. Autoimmun Rev 2011;10(8):482–489.
ILA20-C008 September 2020.
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at http://www.report.novartis.com/
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]